Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

First Epigenetic Test To Diagnose CUP

The EPICUP test is a new tool that helps identify up to 87% of cases of cancer of unknown origin (CUP).

Read More »

Praluent Passes Late-Stage Test

Regeneron and Sanofi announced detailed positive results from ODYSSEY ESCAPE, a Phase 3 trial which evaluated Praluent (alirocumab) Injection.

Read More »

FDA issues emergency use authorization for Zika test

The U.S. Food and Drug Administration issued emergency authorization for a Zika diagnostics test from Swiss drugmaker Roche, skirting normal approval channels as the regulator moves to fight the disease’s spread.

Read More »

More U.S. counties to see Obamacare marketplace monopoly: analysis

Nearly a third of U.S. counties likely will be served by only one insurer that participates in an Affordable Care Act (ACA) marketplace in 2017, according to an analysis published by the Kaiser Family Foundation.

Read More »

Adults with longer-lived parents may age healthier

Adults with longer-lived parents have a lower-than-average risk for problems with the body’s circulatory system in middle age, British researchers have found.

Read More »

Mylan Isn’t Alone: 11 Drugmakers With Off-The-Charts Pricing Power

Mylan is drawing fire for passing off massive price hikes for its EpiPen allergy treatment. But it’s far from being the drug company with the most pricing power.

Read More »

AstraZeneca Puts ‘For Sale’ Sign On U.S. HQ

UK-based AstraZeneca has placed its U.S. headquarters located in Fairfax, Delaware, up for sale. However, the company indicates that it is evaluating several options for the site, including redevelopment, and should not be viewed as abandoning Delaware or even the Fairfax area.

Read More »

FDA warns former Sun Pharma U.S. drug factory over quality concerns

The U.S. Food and Drug Administration has pulled up a former Sun Pharmaceutical drug factory for “knowingly” releasing 27 lots of the hypertension drug clonidine during 2015, despite proof that the raw materials used may have been contaminated.

Read More »

Takeda: Bold, New Access To Medicines Strategy

Takeda announced the launch of an Access to Medicines (AtM) strategy aimed at increasing access to its innovative and potentially life-saving medicines.

Read More »

Theranos to appeal regulatory sanctions on its lab

Blood-testing company Theranos Inc. said it plans to appeal the sanctions imposed by a U.S. regulator on one of its labs alleging its practices jeopardized patient health and safety.

Read More »

Lung cancer doctors eye Keytruda over Opdivo

Recent clinical trial results are likely to lead doctors to treat more patients who have a common form of lung cancer with a Merck drug at the expense of a Bristol-Myers Squibb medication at least until more data emerges, oncologists and analysts say.

Read More »

Hong Kong confirms first case of Zika virus

Hong Kong has confirmed its first case of Zika, putting the Asian financial center on high alert for any spread of the mosquito-borne virus that has wreaked havoc in Latin America, the Caribbean and beyond.

Read More »

Mylan offers discounts on EpiPen after criticism

Mylan NV said it would reduce the out-of-pocket cost of its severe allergy treatment EpiPen through a discount program after lawmakers criticized the drug’s high price.

Read More »

Led by Former Genentech Execs, Denali Banks $130 Million, Initiates Trial and Announces a Handful of Partnerships

Denali Therapeutics announced a broad range of news, including the start of a Phase I trial in Alzheimer’s disease, a number of collaborations and licensing deals, and a $130 million Series B financing round.

Read More »

Job Cuts Loom as Takeda to Shutter Cambridge Office and Quits the UK

After a nine-year presence in the area, Takeda is beginning to wind down its operations in Cambridge, U.K., as the company undergoes a refocusing of its research and development activities that will favor Japan and the United States.

Read More »

Amgen Remains Hush-Hush Over FDA Rejection of Parsabiv

Thousand Oaks, Calif.-based Amgen’s Parsabiv (etelcalcetide) for secondary hyperparathyroidism was rejected by the U.S. Food and Drug Administration, but the company has held off on why or any other details.

Read More »

Novartis: Positive Phase III results for MS drug

Novartis AG said a late-stage study showed its oral once-daily BAF312, or siponimod, reduced the risk of disability progression in a severe form of multiple sclerosis.

Read More »

Biomerica Approved for Listing on the Nasdaq Capital Market

  Company to Begin Trading on Nasdaq on August 26, 2016: Shares Will Trade as BMRA   IRVINE, CA–(Marketwired – August 24, 2016) – Biomerica Inc. (OTCQB: BMRA) today announced that its common stock has been approved for listing on the Nasdaq Capital Market and is expected to commence trading on Nasdaq under the ticker […]

Read More »

Regular nut nibbling linked to low inflammation

Eating a handful of nuts five times per week may reduce inflammation, a condition that contributes to heart disease, diabetes and many other chronic illnesses, say the authors of a recent U.S. study.

Read More »

Pfizer to buy AstraZeneca’s antibiotics business

Pharmaceutical company AstraZeneca has agreed to sell its small molecule antibiotics business to Pfizer Inc. in a deal that could be valued at more than $1.5 billion.

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

August 2018 Focus: Top 200 Meds, Year After Launch, VR/AR and more!


Ad Right Bottom